.Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CD14_Remimazolam.Remimazolam

Information

name:Remimazolam
ATC code:N05CD14
route:intravenous
n-compartments3

Remimazolam is a short-acting benzodiazepine anesthetic used for induction and maintenance of procedural sedation and general anesthesia. It is distinguished by its rapid metabolism via tissue esterases and is approved for use in several countries for procedural sedation and general anesthesia.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult subjects (male and female) following single and multiple intravenous doses.

References

  1. Gao, YQ, et al., & Liu, HC (2023). Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised children. British journal of anaesthesia 131(5) 914–920. DOI:10.1016/j.bja.2023.08.019 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37739904

  2. Kim, SH, & Fechner, J (2022). Remimazolam - current knowledge on a new intravenous benzodiazepine anesthetic agent. Korean journal of anesthesiology 75(4) 307–315. DOI:10.4097/kja.22297 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35585830

  3. Schüttler, J, et al., & Ihmsen, H (2020). Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology 132(4) 636–651. DOI:10.1097/ALN.0000000000003103 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31972655

Revisions


Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos